Infant immunity against viral infections is advanced by the placenta-dependent vertical transfer of maternal antibodies

Standard

Infant immunity against viral infections is advanced by the placenta-dependent vertical transfer of maternal antibodies. / Albrecht, Marie; Pagenkemper, Mirja; Wiessner, Christian; Spohn, Michael; Lütgehetmann, Marc; Jacobsen, Henning; Gabriel, Gülsah; Zazara-Giannou, Dimitra E; Haertel, Christoph; Hecher, Kurt; Diemert, Anke; Arck, Petra Clara.

in: VACCINE, Jahrgang 40, Nr. 11, 08.03.2022, S. 1563-1571.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsatzForschungBegutachtung

Harvard

APA

Vancouver

Bibtex

@article{b746024f61e148d99bfdd33c4621037d,
title = "Infant immunity against viral infections is advanced by the placenta-dependent vertical transfer of maternal antibodies",
abstract = "Neonatal passive immunity, derived from transplacental transfer of IgG antibodies from mother to fetus during pregnancy, can mitigate the risk for severe infections in the early postnatal period. Understanding the placenta as the gateway organ in this process, we aimed to evaluate the influence of specific factors modulating the transplacental IgG transfer rate (TPTR) in 141 mother/neonate pairs. We further evaluated the potential health advantage elicited by maternal IgG with regard to respiratory tract infections during infancy and early childhood. Data and biological samples collected within the prospective longitudinal pregnancy cohort study PRINCE (Prenatal Identification of Children's Health) were used for these analyses. We tested IgG antibody levels against seven pathogens (measles, mumps, rubella, tetanus, diphtheria, pertussis and influenza A) by ELISA and detected seropositivity in 72.6-100% of pregnant women and in 76.3-100% of their neonates, respectively. Cord blood IgG levels reached 137-160% of levels detected in maternal blood. Strikingly, assessment of TPTR for all seven antigens highlighted that TPTR strongly depends on individual placental function. Subsequent in-depth analysis of anti-influenza A IgG revealed a link between cord blood levels and uterine perfusion, measured by uterine artery pulsatility index. Moreover, higher cord blood anti-influenza A IgG levels were associated with a significantly reduced risk for respiratory tract infections during the first six months of life, indicating a high degree of cross-reactivity and possible pathogen-agnostic effects of anti-influenza A antibodies. Taken together, our data suggest that early life immunity is modulated by maternal IgG levels and individual placental features such as perfusion. Vaccination of pregnant women, i.e. against influenza, can increase neonatal antibody levels and hereby protect against early life respiratory infections. Consequently, specific guidelines should evolve in order to safeguard neonates born from pregnancies with poorer placental capacity for vertical transfer of protective antibodies.",
author = "Marie Albrecht and Mirja Pagenkemper and Christian Wiessner and Michael Spohn and Marc L{\"u}tgehetmann and Henning Jacobsen and G{\"u}lsah Gabriel and Zazara-Giannou, {Dimitra E} and Christoph Haertel and Kurt Hecher and Anke Diemert and Arck, {Petra Clara}",
note = "Copyright {\textcopyright} 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.",
year = "2022",
month = mar,
day = "8",
doi = "10.1016/j.vaccine.2020.12.049",
language = "English",
volume = "40",
pages = "1563--1571",
journal = "VACCINE",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "11",

}

RIS

TY - JOUR

T1 - Infant immunity against viral infections is advanced by the placenta-dependent vertical transfer of maternal antibodies

AU - Albrecht, Marie

AU - Pagenkemper, Mirja

AU - Wiessner, Christian

AU - Spohn, Michael

AU - Lütgehetmann, Marc

AU - Jacobsen, Henning

AU - Gabriel, Gülsah

AU - Zazara-Giannou, Dimitra E

AU - Haertel, Christoph

AU - Hecher, Kurt

AU - Diemert, Anke

AU - Arck, Petra Clara

N1 - Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

PY - 2022/3/8

Y1 - 2022/3/8

N2 - Neonatal passive immunity, derived from transplacental transfer of IgG antibodies from mother to fetus during pregnancy, can mitigate the risk for severe infections in the early postnatal period. Understanding the placenta as the gateway organ in this process, we aimed to evaluate the influence of specific factors modulating the transplacental IgG transfer rate (TPTR) in 141 mother/neonate pairs. We further evaluated the potential health advantage elicited by maternal IgG with regard to respiratory tract infections during infancy and early childhood. Data and biological samples collected within the prospective longitudinal pregnancy cohort study PRINCE (Prenatal Identification of Children's Health) were used for these analyses. We tested IgG antibody levels against seven pathogens (measles, mumps, rubella, tetanus, diphtheria, pertussis and influenza A) by ELISA and detected seropositivity in 72.6-100% of pregnant women and in 76.3-100% of their neonates, respectively. Cord blood IgG levels reached 137-160% of levels detected in maternal blood. Strikingly, assessment of TPTR for all seven antigens highlighted that TPTR strongly depends on individual placental function. Subsequent in-depth analysis of anti-influenza A IgG revealed a link between cord blood levels and uterine perfusion, measured by uterine artery pulsatility index. Moreover, higher cord blood anti-influenza A IgG levels were associated with a significantly reduced risk for respiratory tract infections during the first six months of life, indicating a high degree of cross-reactivity and possible pathogen-agnostic effects of anti-influenza A antibodies. Taken together, our data suggest that early life immunity is modulated by maternal IgG levels and individual placental features such as perfusion. Vaccination of pregnant women, i.e. against influenza, can increase neonatal antibody levels and hereby protect against early life respiratory infections. Consequently, specific guidelines should evolve in order to safeguard neonates born from pregnancies with poorer placental capacity for vertical transfer of protective antibodies.

AB - Neonatal passive immunity, derived from transplacental transfer of IgG antibodies from mother to fetus during pregnancy, can mitigate the risk for severe infections in the early postnatal period. Understanding the placenta as the gateway organ in this process, we aimed to evaluate the influence of specific factors modulating the transplacental IgG transfer rate (TPTR) in 141 mother/neonate pairs. We further evaluated the potential health advantage elicited by maternal IgG with regard to respiratory tract infections during infancy and early childhood. Data and biological samples collected within the prospective longitudinal pregnancy cohort study PRINCE (Prenatal Identification of Children's Health) were used for these analyses. We tested IgG antibody levels against seven pathogens (measles, mumps, rubella, tetanus, diphtheria, pertussis and influenza A) by ELISA and detected seropositivity in 72.6-100% of pregnant women and in 76.3-100% of their neonates, respectively. Cord blood IgG levels reached 137-160% of levels detected in maternal blood. Strikingly, assessment of TPTR for all seven antigens highlighted that TPTR strongly depends on individual placental function. Subsequent in-depth analysis of anti-influenza A IgG revealed a link between cord blood levels and uterine perfusion, measured by uterine artery pulsatility index. Moreover, higher cord blood anti-influenza A IgG levels were associated with a significantly reduced risk for respiratory tract infections during the first six months of life, indicating a high degree of cross-reactivity and possible pathogen-agnostic effects of anti-influenza A antibodies. Taken together, our data suggest that early life immunity is modulated by maternal IgG levels and individual placental features such as perfusion. Vaccination of pregnant women, i.e. against influenza, can increase neonatal antibody levels and hereby protect against early life respiratory infections. Consequently, specific guidelines should evolve in order to safeguard neonates born from pregnancies with poorer placental capacity for vertical transfer of protective antibodies.

U2 - 10.1016/j.vaccine.2020.12.049

DO - 10.1016/j.vaccine.2020.12.049

M3 - SCORING: Journal article

C2 - 33431223

VL - 40

SP - 1563

EP - 1571

JO - VACCINE

JF - VACCINE

SN - 0264-410X

IS - 11

ER -